arrow
B

Beatrice Berti

centro clinico nemo pediatrico
H指数:20
被引数:1,314

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry

Onasemnogene Abeparvovec 在I型脊髓性肌萎缩症中的研究:来自意大利登记系统的24个月随访结果

2026-03-190
OAAI
Development of the “SMA NNE,” a short neonatal neurological examination for newborns with spinal muscular atrophy

“SMA NNE”的研制,一种用于患有脊髓性肌萎缩症新生儿的简短神经学检查方法

2025-08-190
OAAI
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study

接受疾病改善疗法的I型SMA患者管饲的预后因素: 一项队列研究

2024-08-290
OAAI
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?

通过新生儿SMA筛查确定的婴儿早期神经系统体征: 它们能预测结果吗?

2024-04-181
OAAI
Onasemnogene abeparvovec in spinal muscular atrophy : predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies

脊髓性肌萎缩症中的Onasemnogene abeparvovec: 幼稚的脊髓性肌萎缩症患者和从其他疗法转换后的疗效和安全性的预测因子

2023-05-0119
OAAI
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening

通过新生儿筛查确定的脊髓性肌萎缩症新生儿的神经系统评估

2022-05-0626
OAAI
Body mass index in type 2 spinal muscular atrophy: a longitudinal study

2型脊髓性肌萎缩症的体重指数: 一项纵向研究

2022-01-193
OAAI
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module

1型SMA患者的口腔和吞咽能力工具 (OrSAT): 新模块的开发

2021-05-1921
OAAI
Type I SMA new natural history: long-term data in nusinersen-treated patients

I型SMA新自然史: nusinersen治疗患者的长期数据

2021-02-0648
OAAI
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data

Nusinersen治疗1型脊髓性肌萎缩症: 12个月的真实数据

2019-07-0898
PREAI